PLEKHA5

Across TCGA pan-cancer cohorts, PLEKHA5 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PLEKHA5’s most consistent transcriptional readouts.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where PLEKHA5 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PLEKHA5 is over-expressed in tumor, although a few such as OV and CCRCC show the opposite, repressed pattern.

OV, CCRCC, and PDAC are the cancer types where PLEKHA5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLEKHA5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
OV	All	All	−0.467	.037	2	view →
CCRCC	Male	All	−0.250	<.001	2	view →
PDAC	Male	II,III,IV	+0.248	.018	2	view →
COAD	Male	IV	+0.385	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

PLEKHA5–OV

Open the OV breakdown →